PharmAla Biotech at Water Tower Research Virtual Insights Conference: supply moat

On Tuesday, 22 September 2026, PharmAla Biotech (MDMA) spoke at the Water Tower Research Virtual Insights Conference, outlining a dual strategy that combines maintaining its position as the leading producer of clinical-grade MDMA with developing a pipeline of novel entactogens and related compounds. CEO Nick Kadysh reported progress in both areas, but acknowledged that U.S. commercial sales remain limited, relying on regulation, partnerships, and execution to move forward.

As the world's largest supplier of clinical-grade MDMA, PharmAla now provides supplies to approximately 35 trials worldwide. A notable 30% of these customers are repeat clients, indicating a strong preference for the company's reliability and regulatory compliance. PharmAla's "drugs for data" business model ties discounts to robust protocols and full access to safety and efficacy data, fostering long-term relationships with customers, including major academic institutions and government bodies.

The company's Jupiter transaction for ALA-002 could yield up to CAD 100 million in potential milestones, with an initial payment already received, contingent on meeting specific development milestones. Additionally, PharmAla's Australian joint venture, Cortexa, has become the leading supplier in Australia's Authorised Prescriber Scheme and is the exclusive supplier of MDMA and psilocybin to Emyria, the country's largest clinic network customer.

These strategic partnerships and supply chain strengths underscore PharmAla's commitment to delivering both clinical-grade MDMA and innovative compounds backed by strong scientific data.